NBIX Relative Valuation
NBIX's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, NBIX is overvalued; if below, it's undervalued.
Historical Valuation
Neurocrine Biosciences Inc (NBIX) is now in the Undervalued zone, suggesting that its current forward PE ratio of 16.99 is considered Undervalued compared with the five-year average of 22.10. The fair price of Neurocrine Biosciences Inc (NBIX) is between 159.63 to 239.38 according to relative valuation methord. Compared to the current price of 151.96 USD , Neurocrine Biosciences Inc is Undervalued By 4.81%.
Relative Value
Fair Zone
159.63-239.38
Current Price：151.96
4.81%
Undervalued
17.24
PE
1Y
3Y
5Y
Trailing
Forward
21.32
EV/EBITDA
Neurocrine Biosciences Inc. (NBIX) has a current EV/EBITDA of 21.32. The 5-year average EV/EBITDA is 22.24. The thresholds are as follows: Strongly Undervalued below 8.54, Undervalued between 8.54 and 15.39, Fairly Valued between 29.09 and 15.39, Overvalued between 29.09 and 35.94, and Strongly Overvalued above 35.94. The current Forward EV/EBITDA of 21.32 falls within the Historic Trend Line -Fairly Valued range.
17.41
EV/EBIT
Neurocrine Biosciences Inc. (NBIX) has a current EV/EBIT of 17.41. The 5-year average EV/EBIT is 23.87. The thresholds are as follows: Strongly Undervalued below 9.21, Undervalued between 9.21 and 16.54, Fairly Valued between 31.19 and 16.54, Overvalued between 31.19 and 38.52, and Strongly Overvalued above 38.52. The current Forward EV/EBIT of 17.41 falls within the Historic Trend Line -Fairly Valued range.
4.59
PS
Neurocrine Biosciences Inc. (NBIX) has a current PS of 4.59. The 5-year average PS is 5.78. The thresholds are as follows: Strongly Undervalued below 3.42, Undervalued between 3.42 and 4.60, Fairly Valued between 6.96 and 4.60, Overvalued between 6.96 and 8.14, and Strongly Overvalued above 8.14. The current Forward PS of 4.59 falls within the Undervalued range.
17.68
P/OCF
Neurocrine Biosciences Inc. (NBIX) has a current P/OCF of 17.68. The 5-year average P/OCF is 21.81. The thresholds are as follows: Strongly Undervalued below 14.00, Undervalued between 14.00 and 17.91, Fairly Valued between 25.71 and 17.91, Overvalued between 25.71 and 29.62, and Strongly Overvalued above 29.62. The current Forward P/OCF of 17.68 falls within the Undervalued range.
16.59
P/FCF
Neurocrine Biosciences Inc. (NBIX) has a current P/FCF of 16.59. The 5-year average P/FCF is 23.93. The thresholds are as follows: Strongly Undervalued below 15.88, Undervalued between 15.88 and 19.90, Fairly Valued between 27.96 and 19.90, Overvalued between 27.96 and 31.98, and Strongly Overvalued above 31.98. The current Forward P/FCF of 16.59 falls within the Undervalued range.
Neurocrine Biosciences Inc (NBIX) has a current Price-to-Book (P/B) ratio of 5.04. Compared to its 3-year average P/B ratio of 5.39 , the current P/B ratio is approximately -6.35% higher. Relative to its 5-year average P/B ratio of 6.09, the current P/B ratio is about -17.11% higher. Neurocrine Biosciences Inc (NBIX) has a Forward Free Cash Flow (FCF) yield of approximately 0.00%. Compared to its 3-year average FCF yield of 3.52%, the current FCF yield is approximately -100.00% lower. Relative to its 5-year average FCF yield of 3.06% , the current FCF yield is about -100.00% lower.
5.12
P/B
Median3y
5.39
Median5y
6.09
3.91
FCF Yield
Median3y
3.52
Median5y
3.06
Competitors Valuation Multiple
The average P/S ratio for NBIX's competitors is , providing a benchmark for relative valuation. Neurocrine Biosciences Inc Corp (NBIX) exhibits a P/S ratio of , which is NaN% above the industry average. Given its robust revenue growth of 27.78%, this premium appears sustainable.
P/S
P/E
EV/EBITDA
EV/EBIT
P/S
Revenue Growth
Market Cap
Performance Decomposition
1Y
3Y
5Y
Market capitalization of NBIX increased by 12.98% over the past 1 year. The primary factor behind the change was an increase in Revenue Growth from 622.10M to 794.90M.
The secondary factor is the Margin Expansion, contributed 26.37%to the performance.
Overall, the performance of NBIX in the past 1 year is driven by Revenue Growth. Which is more sustainable.
People Also Watch
FAQ
Is Neurocrine Biosciences Inc (NBIX) currently overvalued or undervalued?
What is Neurocrine Biosciences Inc (NBIX) fair value?
How does NBIX's valuation metrics compare to the industry average?
What is the current P/B ratio for Neurocrine Biosciences Inc (NBIX) as of Dec 05 2025?
What is the current FCF Yield for Neurocrine Biosciences Inc (NBIX) as of Dec 05 2025?
What is the current Forward P/E ratio for Neurocrine Biosciences Inc (NBIX) as of Dec 05 2025?